Innoviva's average Accounts Receivable for the
three
months ended in Mar. 2024 was $45.2 Mil. Innoviva's Revenue for the
three
months ended in Mar. 2024 was $77.5 Mil.
Hence, Innoviva's Days Sales Outstanding for the
three
months ended in Mar. 2024 was 53.26.
The historical rank and industry rank for Innoviva's Days Sales Outstanding or its related term are showing as below:
INVA'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.02 Med: 99.24 Max: 301.46
Current: 73.81
During the past 13 years, Innoviva's highest Days Sales Outstanding was 301.46. The lowest was 14.02. And the median was 99.24.
INVA's Days Sales Outstanding is ranked worse than 51.34% of 894
companies
in the Biotechnology industry
Industry Median: 72.38
vs INVA: 73.81
Innoviva's Days Sales Outstanding
increased
from Mar. 2023 (50.90) to Mar. 2024 (53.26).
Innoviva Days Sales Outstanding Historical Data
The historical data trend for Innoviva's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Innoviva's Days Sales Outstanding
For the Biotechnology subindustry, Innoviva's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innoviva's Days Sales Outstanding Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innoviva's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Innoviva's Days Sales Outstanding falls into.
Innoviva Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innoviva (NAS:INVA) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Innoviva Days Sales Outstanding Related Terms
Thank you for viewing the detailed overview of Innoviva's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.
Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INVA has been successfully added to your 